|By PR Newswire||
|April 11, 2014 09:53 AM EDT||
OXFORD, England, April 11, 2014 /PRNewswire/ --
PharmaVentures is pleased to announce that it has been appointed by Novartis as advisors on the future options for its UK Horsham site. These options could include reusing part of the site as a science or business park, thereby creating a legacy with the possibility of creating some highly skilled jobs for the area in the future. PharmaVentures will provide expert advice on the feasibility of doing this, and to help identify potential partners.
See the Novartis press release here.
Dr Fintan Walton, Chief Executive, PharmaVentures, said "The Novartis Horsham site is a perfect location for a high technology park. Novartis has built state of the art facilities, suitable for pharmaceutical / life science or other high technology businesses. With such high quality facilities, we expect interest from both universities and research institutes." Dr Walton added "The site would also be ideal as a business park as Horsham is an attractive location due to its strong international links through Gatwick airport and its proximity to London."
PharmaVentures is a premier transaction advisory firm and a leader in partnering, M&A deals and strategic alliances. Their unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes them uniquely placed to support businesses in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success in transactions.
Find out more http://www.pharmaventures.com
Our services include:
• M&A (divestments, mergers, acquisitions and strategic transactions)
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
• Licensing (in and out licensing)
• Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
Now in its 23rd year, PharmaVentures is based in Oxford, UK, with offices in London and San Francisco.
For further information, contact:
Dr Fintan Walton